Paclitaxel/Encequidar mesylate

N/A

Report date: 2025/12/09 20:00:11

Base Information

Drug NamePaclitaxel/Encequidar mesylate
Drug Alias NamePaclitaxel and HM-30181AHM-30181A/紫杉醇KR-30031 + paclitaxel紫杉醇-HM-30181APaclitaxel•HM-30181A +[14] 
ClassificationSmall molecules
Mechanisms of ActionP-glycoprotein 1 inhibitorsTubulin inhibitors
TargetsP-glycoprotein 1Tubulin
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsAdenocarcinoma +[4] 
Global Approved IndicationsBreast NeoplasmsAdenocarcinoma
Approved Indications in ChinaN/A
Original Approved Country/TerritorySingapore
Original Approved Date2019/08/01
Country/TerritoryUnited StatesSingaporeTaiwan +[8] 
CombinationsYes Encequidar mesylatePaclitaxel
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAthenex IncPharmaEssentia Corp
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast NeoplasmsAdenocarcinoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL01
Related LinksN/A